Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Early High Efficacy Treatment in Multiple Sclerosis Is the Best Predictor of Future Disease Activity Over 1 and 2 Years in a Norwegian Population-Based Registry
Cecilia Smith Simonsen, Heidi Øyen Flemmen, Line Broch, et al.
Frontiers in Neurology (2021) Vol. 12
Open Access | Times Cited: 74

Showing 1-25 of 74 citing articles:

Multiple sclerosis: time for early treatment with high-efficacy drugs
Krzysztof Selmaj, Bruce Cree, Michael Barnett, et al.
Journal of Neurology (2023) Vol. 271, Iss. 1, pp. 105-115
Open Access | Times Cited: 25
Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption
B. Singer, Jenny Feng, Horacio Chiong-Rivero
Journal of Neurology (2024) Vol. 271, Iss. 6, pp. 3116-3130
Open Access | Times Cited: 8
Investigating Whether Dissemination in Time Is Essential to Diagnose Relapsing Multiple Sclerosis
Wallace Brownlee, Michael A. Foster, Giuseppe Pontillo, et al.
Neurology (2025) Vol. 104, Iss. 7
Closed Access | Times Cited: 1
Escalation vs. Early Intense Therapy in Multiple Sclerosis
Bonaventura Casanova, Carlos Quintanilla‐Bordás, Francisco Gascón
Journal of Personalized Medicine (2022) Vol. 12, Iss. 1, pp. 119-119
Open Access | Times Cited: 32
Current Updates on the Diagnosis and Management of Multiple Sclerosis for the General Neurologist
Archit Baskaran, Elena Grebenciucova, Thomas Shoemaker, et al.
Journal of Clinical Neurology (2023) Vol. 19, Iss. 3, pp. 217-217
Open Access | Times Cited: 17
Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review
Óscar Fernández, Per Soelberg Sørensen, Gıancarlo Comı, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
New drugs for multiple sclerosis: new treatment algorithms
Bruce Cree, Hans‐Peter Hartung, Michael Barnett
Current Opinion in Neurology (2022) Vol. 35, Iss. 3, pp. 262-270
Open Access | Times Cited: 27
No Evidence of Disease Activity (NEDA) as a Clinical Assessment Tool for Multiple Sclerosis: Clinician and Patient Perspectives [Narrative Review]
Scott D. Newsome, Cherie Binns, Ulrike W. Kaunzner, et al.
Neurology and Therapy (2023) Vol. 12, Iss. 6, pp. 1909-1935
Open Access | Times Cited: 13
Identification and management of subclinical disease activity in early multiple sclerosis: a review
Daniel Ontaneda, Tanuja Chitnis, Kottil Rammohan, et al.
Journal of Neurology (2023) Vol. 271, Iss. 4, pp. 1497-1514
Open Access | Times Cited: 13
Treatment De-escalation in Relapsing-Remitting Multiple Sclerosis: An Observational Study
Jannis Müller, Sifat Sharmin, Johannes Lorscheider, et al.
CNS Drugs (2025)
Open Access
Rethinking Shared Decision-Making in Multiple Sclerosis Care: A Critical Examination
William L. Conte
Multiple Sclerosis and Related Disorders (2025), pp. 106417-106417
Closed Access
The mosaic of autoimmunity – Finally discussing in person. The 13th international congress on autoimmunity 2022 (AUTO13) Athens
Naim Mahroum, Abdulrahman Elsalti, Abdulkarim Alwani, et al.
Autoimmunity Reviews (2022) Vol. 21, Iss. 10, pp. 103166-103166
Open Access | Times Cited: 20
Insights for Healthcare Providers on Shared Decision-Making in Multiple Sclerosis: A Narrative Review
Sharon Stoll, Kathleen Costello, Scott D. Newsome, et al.
Neurology and Therapy (2024) Vol. 13, Iss. 1, pp. 21-37
Open Access | Times Cited: 4
Advancements in multiple sclerosis
Turlough Montague, James Drummond, Karl Ng, et al.
Internal Medicine Journal (2025)
Open Access
Shifts in treatment initiation patterns among newly diagnosed multiple sclerosis patients in Germany: a claims data analysis from 2017 to 2022
Ann-Sophie Stratil, Steffeni Papukchieva, Natalie Joschko, et al.
Therapeutic Advances in Neurological Disorders (2025) Vol. 18
Open Access
The Czech National MS Registry (ReMuS): Data trends in multiple sclerosis patients whose first disease-modifying therapies were initiated from 2013 to 2021
Dominika Šťastná, Jiří Drahota, Michal Lauer, et al.
Biomedical Papers (2023) Vol. 168, Iss. 3, pp. 262-270
Open Access | Times Cited: 9
Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023
José Meca-Lallana, Sergio Martínez‐Yélamos, Sara Eichau, et al.
Neurología (English Edition) (2024) Vol. 39, Iss. 2, pp. 196-208
Open Access | Times Cited: 3
Shifting from the treat-to-target to the early highly effective treatment approach in patients with multiple sclerosis – real-world evidence from Germany
Steffeni Papukchieva, Ann-Sophie Stratil, Maria Kahn, et al.
Therapeutic Advances in Neurological Disorders (2024) Vol. 17
Open Access | Times Cited: 3
Beyond lines of treatment: embracing early high-efficacy disease-modifying treatments for multiple sclerosis management
Celia Oreja‐Guevara, Sergio Martínez‐Yélamos, Sara Eichau, et al.
Therapeutic Advances in Neurological Disorders (2024) Vol. 17
Open Access | Times Cited: 3
Early rituximab treatment reduces long-term disability in aquaporin-4 antibody-positive neuromyelitis optica spectrum
Su Yeon Park, Young Nam Kwon, Sun‐Young Kim, et al.
Journal of Neurology Neurosurgery & Psychiatry (2023) Vol. 94, Iss. 10, pp. 800-805
Closed Access | Times Cited: 8
Does initial high efficacy therapy in multiple sclerosis surpass escalation treatment strategy? A comparison of patients with relapsing-remitting multiple sclerosis in the Czech and Swedish national multiple sclerosis registries
Tereza Hrnčiarová, Jiří Drahota, Tim Spelman, et al.
Multiple Sclerosis and Related Disorders (2023) Vol. 76, pp. 104803-104803
Closed Access | Times Cited: 8
The disease-modifying therapy utilisation and cost trend for multiple sclerosis in Australia between 2013 and 2022
Ting Zhao, Bruce Taylor, Julie A. Campbell, et al.
Multiple Sclerosis Journal (2023) Vol. 30, Iss. 1, pp. 80-88
Closed Access | Times Cited: 7
Documento de consenso de la Sociedad Española de Neurología sobre el tratamiento de la esclerosis múltiple y manejo holístico del paciente 2023
José Meca-Lallana, Sergio Martínez‐Yélamos, Sara Eichau, et al.
Neurología (2024) Vol. 39, Iss. 2, pp. 196-208
Open Access | Times Cited: 2
Escalating to medium‐ versus high‐efficacy disease modifying therapy after low‐efficacy treatment in relapsing remitting multiple sclerosis
Jannis Müller, Izanne Roos, Tomáš Kalinčík, et al.
Brain and Behavior (2024) Vol. 14, Iss. 5
Open Access | Times Cited: 2
Real-world evidence from Germany and the United States: Treatment initiation on low-efficacy versus high-efficacy therapies in patients with multiple sclerosis
Steffeni Papukchieva, Hyung-Do Kim, Ann-Sophie Stratil, et al.
Multiple Sclerosis and Related Disorders (2024) Vol. 88, pp. 105751-105751
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top